Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 17;31(6):3495-3512.
doi: 10.3390/curroncol31060258.

A Review of Immunotherapy in Non-Small-Cell Lung Cancer

Mariana Pilon Capella  1 , Steph A Pang  1 , Marcos A Magalhaes  2 , Khashayar Esfahani  1   3
Affiliations
Review

A Review of Immunotherapy in Non-Small-Cell Lung Cancer

Mariana Pilon Capella et al. Curr Oncol. .

Abstract

Cancer immunotherapy in the form of immune checkpoint inhibitors has led to a dramatic increase in the survival of patients with lung cancer across all stages. Over the past decade, the field has experienced rapid maturation; however, several challenges continue to complicate patient management. This review aims to highlight the data that led to this dramatic shift in practice as well as to focus on key challenges. These include determining the optimal therapy duration, managing frail patients or those with brain metastases, addressing the challenges posed by immune-related adverse events, and defining the various patterns of clinical and radiological responses to immunotherapy.

Keywords: CTLA-4; PD-1; immunotherapy; non-small-cell lung cancer; squamous cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. International Agency for Research on Cancer . GLOBOCAN Lung Cancer Facts Sheet. International Agency for Research on Cancer; Lyon, France: 2020.
    1. Zappa C., Mousa S.A. Non-small cell lung cancer: Current treatment and future advances. Transl. Lung Cancer Res. 2016;5:288–300. doi: 10.21037/tlcr.2016.06.07. - DOI - PMC - PubMed
    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Canadian Cancer Statistics, 2022. CA Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. Horn L., Spigel D.R., Vokes E.E., Holgado E., Ready N., Steins M., Poddubskaya E., Borghaei H., Felip E., Paz-Ares L., et al. Nivolumab versus Docetaxel in Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes from Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) J. Clin. Oncol. 2017;35:3924–3933. doi: 10.1200/JCO.2017.74.3062. - DOI - PMC - PubMed
    1. Herbst R.S., Baas P., Kim D.-W., Felip E., Pérez-Gracia J.L., Han J.-Y., Molina J., Kim J.-H., Arvis C.D., Ahn M.-J., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet. 2016;387:1540–1550. doi: 10.1016/S0140-6736(15)01281-7. - DOI - PubMed

MeSH terms

Substances